Smart drug shows promising results for treatment of metastatic triple-negative breast cancer

https://www.facingourrisk.org/XRAY/smart-drug-metastatic-triple-negative-breast-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1814213

THIS INFORMATION HAS BEEN UPDATED on 04/27/20: Based on the results from the study reviewed in this XRAY, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hizy (Trodelvy), as a treatment for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

Questions To Ask Your Health Care Provider

Are any new therapies for TNBC appropriate for my treatment?
Do I qualify for any clinical trials?
What are the risks and benefits of participating in a clinical trial?
What is the expected length of progression-free survival for my line of treatment?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.